Biotech Values

[poorgradstudent]

Vytorin:

It is going to take a massive hit.

What will be interesting, however, is to see the remaining sales level. Having had a couple of conversations about this, it appears that many academic centers are going to axe Vytorin use. I would suspect that the remaining sales of this drug will primarily be to country bumpkin doctors who don't keep up with the literature and private practice conglomerates that may "benefit" from continued prescriptions. I've always wondered how big this collection of docs are, and Vytorin sales may be my best attempt to determine their numbers.